Alignment Healthcare CEO Sells $2.1 Million in Shares. Here's What Investors Should Know
Key Points
The CEO of Alignment Healthcare reported selling 118,000 shares indirectly on March 23, 2026, generating a transaction value of approximately $2.06 million.
All shares were sold indirectly through the JEK Trust, with no direct holdings involved in this sale; post-transaction, indirect holdings stand at 2,354,641 shares and direct holdings at 1,784,868 shares, as reported in the filing.
The sale was part of a trading plan adopted last year.
- 10 stocks we like better than Alignment Healthcare ›
John E. Kao, Chief Executive Officer of Alignment Healthcare (NASDAQ:ALHC), reported the indirect sale of 118,000 shares for a transaction value of about $2.06 million, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (indirect) | 118,000 |
| Transaction value | $2.1 million |
| Post-transaction shares (direct) | 1,784,868 |
| Post-transaction shares (indirect) | 2,354,641 |
| Post-transaction value (direct ownership) | $31.3 million |
Transaction value based on SEC Form 4 reported price ($17.48); post-transaction value based on March 23, 2026 market close ($17.51).
Key questions
- How does this sale compare to John E. Kao’s historical trading activity?
The 118,000 shares sold are below the recent median sell size of 180,000 shares per transaction observed since May 2025, and also below the maximum single-trade size of 605,648 shares over this period. - What is the impact on the insider’s ownership structure?
After the transaction, Kao retains 1,784,868 shares directly and 2,354,641 shares indirectly (via JEK Trust), maintaining a total beneficial ownership position of 4,139,509 shares, as reported in the filing. - Were the shares sold under a pre-arranged trading plan?
Yes. The footnote specifies that the shares were sold as part of a plan adopted in November of last year. - Did market conditions play a material role in the timing or pricing of this transaction?
Shares were sold at around $17.48 per share, consistent with the closing price of $17.51 on March 23, 2026; this price level reflects a largely flat one-year return (+0.3%), suggesting stable market conditions at the time of sale.
Company overview
| Metric | Value |
|---|---|
| Market capitalization | $3.58 billion |
| Revenue (TTM) | $3.95 billion |
| Net income (TTM) | -$0.72 million |
* 1-year price change calculated as of market close March 23, 2026.
Company snapshot
- Alignment Healthcare offers Medicare Advantage plans and coordinates covered healthcare services, including professional, institutional, and ancillary care for seniors in California, North Carolina, and Nevada.
- The firm operates a technology-enabled, consumer-centric healthcare platform that generates revenue primarily through Medicare Advantage premiums and care coordination services.
- It targets seniors and individuals eligible for Medicare, with a focus on those seeking comprehensive, personalized healthcare solutions.
Alignment Healthcare is a Medicare Advantage provider leveraging a technology-driven platform to deliver personalized healthcare to seniors. With operations concentrated in select U.S. states, the company differentiates itself through consumer-centric service and integrated care coordination.
What this transaction means for investors
Kao’s looks measured and consistent with routine selling activity. It was executed under a prearranged trading plan and represents a small portion of his overall exposure, with more than 4.1 million shares still held across direct and indirect ownership. For long-term investors, the more relevant signal here is not the sale itself, but whether Alignment Healthcare can sustain its rapid growth while moving toward consistent profitability.
The company’s full-year revenue reached about $3.95 billion in 2025, up more than 46% year over year, with adjusted EBITDA of roughly $110 million and a notable step toward positive free cash flow. Membership growth also remains strong, with guidance implying continued double-digit expansion into 2026 alongside projected revenue of roughly $5.1 billion to $5.2 billion. Still, margins remain thin and expanded them seems a clear priority for the firm, as Kao acknowledged in the latest earnings report.
Ultimately, it seems like growth is intact, and the real upside hinges on margin expansion. If Alignment can translate scale into profitability, the current steady stock performance could prove more of a pause than a ceiling.
Should you buy stock in Alignment Healthcare right now?
Before you buy stock in Alignment Healthcare, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alignment Healthcare wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $503,592!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,076,767!*
Now, it’s worth noting Stock Advisor’s total average return is 913% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 24, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
